Innate Pharma Announces Conference Call and Webcast for Q3 2021 Business Update
09 Novembre 2021 - 7:00AM
Business Wire
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA)
(“Innate” or the “Company”), today announced that the
Company will hold a conference call on Tuesday, November 16, 2021,
at 2 p.m. CET / 8 a.m. ET, to give an update on business progress
during the third quarter of 2021.
Participating in the call will be Innate’s Chief Executive
Officer Mondher Mahjoubi, MD and Chief Medical Officer Joyson
Karakunnel, MD, MSc, FACP.
Details for the Virtual
Event
The live webcast will
be available at the following link:
https://event.on24.com/wcc/r/3492971/A9D12AE41D08D16F4096ACD3C27EC089
Participants may also join via telephone using
the following dial in numbers: France: +33 8056 20 704 United
States: +1 646 904 5544 All other locations: +1 929 526 1599 Access
code: 043615
This information can also be found on the investors section of
the Innate website, www.innate-pharma.com. A replay of the webcast
will be available on the Company website following the event.
About Innate Pharma: Innate Pharma S.A. is a global,
clinical-stage oncology-focused biotech company dedicated to
improving treatment and clinical outcomes for patients through
therapeutic antibodies that harness the immune system to fight
cancer.
Innate Pharma’s broad pipeline of antibodies includes several
potentially first-in-class clinical and preclinical candidates in
cancers with high unmet medical need.
Innate is a pioneer in the understanding of Natural Killer cell
biology and has expanded its expertise in the tumor
microenvironment and tumor-antigens, as well as antibody
engineering. This innovative approach has resulted in a diversified
proprietary portfolio and major alliances with leaders in the
biopharmaceutical industry including Bristol-Myers Squibb, Novo
Nordisk A/S, Sanofi, and a multi-products collaboration with
AstraZeneca.
Headquartered in Marseille, France with a US office in
Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq
in the US.
Learn more about Innate Pharma at www.innate-pharma.com.
Information about Innate Pharma shares:
ISIN code
FR0010331421
Ticker code
Euronext: IPH Nasdaq: IPHA
LEI
9695002Y8420ZB8HJE29
Disclaimer on forward-looking information and risk
factors:
This press release contains certain forward-looking statements,
including those within the meaning of the Private Securities
Litigation Reform Act of 1995. The use of certain words, including
“believe,” “potential,” “expect” and “will” and similar
expressions, is intended to identify forward-looking statements.
Although the company believes its expectations are based on
reasonable assumptions, these forward-looking statements are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. These
risks and uncertainties include, among other things, the
uncertainties inherent in research and development, including
related to safety, progression of and results from its ongoing and
planned clinical trials and preclinical studies, review and
approvals by regulatory authorities of its product candidates, the
Company’s commercialization efforts, the Company’s continued
ability to raise capital to fund its development and the overall
impact of the COVID-19 outbreak on the global healthcare system as
well as the Company’s business, financial condition and results of
operations. For an additional discussion of risks and uncertainties
which could cause the company's actual results, financial
condition, performance or achievements to differ from those
contained in the forward-looking statements, please refer to the
Risk Factors (“Facteurs de Risque") section of the Universal
Registration Document filed with the French Financial Markets
Authority (“AMF”), which is available on the AMF website
http://www.amf-france.org or on Innate Pharma’s website, and public
filings and reports filed with the U.S. Securities and Exchange
Commission (“SEC”), including the Company’s Annual Report on Form
20-F for the year ended December 31, 2020, and subsequent filings
and reports filed with the AMF or SEC, or otherwise made public, by
the Company.
This press release and the information contained herein do not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe to shares in Innate Pharma in any country.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211108006164/en/
Investors Innate
Pharma Henry Wheeler
+33 761 88 38 74
Henry.wheeler@innate-pharma.fr
Media Innate Pharma
Tracy Rossin (Global/US) +1 240 801 0076
Tracy.Rossin@innate-pharma.com
ATCG Press Marie Puvieux (France) +33 (0)9 81 87 46 72
innate-pharma@atcg-partners.com
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024